Table 4.

Analysis of the mutational pattern of functionally rearranged IgVH genes in monoclonal B-cell PTLDs

IgVH Germ-line gene
% of mutation
Observed R/S*
Expected R/S†
P‡
Case
Histology
FR/CDR
PB
PM
2618   P-PTLD   3-30.3   5.64   FR   1.33   2.97   <.001   .028  
     CDR   2.50   3.87   .109   .109  
2916   P-PTLD   5-51   2.77   FR   0.95   2.96   .001   .002  
     CDR   1.43   4.92   .079   .841  
3468   P-PTLD   3-07   12.3   FR   1.60   3.10   .069   .089  
     CDR   1.00   4.11   .187   .685  
3471   P-PTLD   3-30   12.1   FR   0.57   3.17   .001   <.001  
     CDR   1.00   3.44   .200   .453  
3515   P-PTLD   3-15   10.3   FR   0.60   2.90   <.001   <.001  
     CDR   8.00   3.45   .029   .027  
3519   P-PTLD   3-30   10.3   FR   2.50   3.13   .107   .123  
     CDR   2.50   3.87   .083   .113  
2798   DLBCL, CB   4-34   23.2   FR   1.30   2.74   <.001   <.001  
     CDR   18.0   4.39   .001   <.001  
2898   DLBCL, CB   4-34   11.8   FR   1.22   2.74   .059   .087  
     CDR   0.40   4.39   .390   .97  
2912   DLBCL, CB   5-51   4.06   FR   3.00   3.35   .155   .211  
     CDR   4.00   3.58   .150   .170  
2914   DLBCL, CB   3-74   8.64   FR   1.50   2.99   .045   .048  
     CDR   8.00   3.69   .023   .022  
3459   DLBCL, CB   1-69   17.6   FR   0.95   2.96   <.001   <.001  
     CDR   1.80   3.55   .145   .502  
3466   DLBCL, CB   1-f   3.73   FR   4.00   3.12   .122   .115  
     CDR   Infinite   3.56   .039   .048  
3518   DLBCL, CB   3-33   4.41   FR   5.00   2.97   .156   .191  
     CDR   2.00   4.28   .151   .176  
3522   DLBCL, CB   4-34   6.87   FR   1.40   2.76   .054   .517  
     CDR   1.00   4.39   .244   .060  
3523   DLBCL, CB   1-46   2.71   FR   Infinite   2.98   .246   .328  
     CDR   3.00   4.40   .125   .104  
3524   DLBCL, CB   3-15   14.9   FR   0.94   2.90   <.001   <.001  
     CDR   1.80   3.44   .143   .393  
3528   DLBCL, CB   1-18   8.11   FR   1.67   2.93   .046   .059  
     CDR   7.00   4.05   .073   .089  
3530   DLBCL, CB   3-07   24.1   FR   2.00   3.07   .077   .216  
     CDR   6.00   4.79   .033   .095  
2616   DLBCL, IB   3-30   9.68   FR   1.20   3.13   .002   .002  
     CDR   6.33   3.87   .013   .013  
2799   DLBCL, IB   4-34   11.6   FR   1.00   2.82   .062   .092  
     CDR   3.00   4.39   .077   .919  
2802   DLBCL, IB   LSG6.1   5.28   FR   1.00   3.23   .223   .208  
     CDR   Infinite   2.95   .293   .307  
2803   DLBCL, IB   3-11   2.80   FR   Infinite   2.95   .118   .095  
     CDR   6.00   4.34   .036   .025  
2911   DLBCL, IB   3-15   2.25   FR   0   3.18   .0549   .027  
     CDR   Infinite   2.95   .421   .421  
3469   DLBCL, IB   3-15   17.2   FR   1.22   3.23   .070   .092  
     CDR   2.00   2.95   .145   .705  
3476   DLBCL, IB   4-04   8.62   FR   1.60   2.70   .032   .0543  
     CDR   3.50   4.09   .103   .119  
3517   DLBCL, IB   3-23   7.80   FR   0.80   2.99   <.001   <.001  
     CDR   6.00   3.55   <.001   <.001  
3525   DLBCL, IB   4-34   2.12   FR   4.00   2.76   .296   .655  
     CDR   0   4.40   .312   .844  
2617   BL/BLL   4-59   5.45   FR   2.00   3.12   .235   .333  
     CDR   2.00   2.98   .305   .504  
2890   BL/BLL   4-61   12.0   FR   2.00   2.75   .053   .066  
 
 
 
 		 CDR
 		 Infinite
 		 4.39
 		 .011
 		 .011
 
IgVH Germ-line gene
% of mutation
Observed R/S*
Expected R/S†
P‡
Case
Histology
FR/CDR
PB
PM
2618   P-PTLD   3-30.3   5.64   FR   1.33   2.97   <.001   .028  
     CDR   2.50   3.87   .109   .109  
2916   P-PTLD   5-51   2.77   FR   0.95   2.96   .001   .002  
     CDR   1.43   4.92   .079   .841  
3468   P-PTLD   3-07   12.3   FR   1.60   3.10   .069   .089  
     CDR   1.00   4.11   .187   .685  
3471   P-PTLD   3-30   12.1   FR   0.57   3.17   .001   <.001  
     CDR   1.00   3.44   .200   .453  
3515   P-PTLD   3-15   10.3   FR   0.60   2.90   <.001   <.001  
     CDR   8.00   3.45   .029   .027  
3519   P-PTLD   3-30   10.3   FR   2.50   3.13   .107   .123  
     CDR   2.50   3.87   .083   .113  
2798   DLBCL, CB   4-34   23.2   FR   1.30   2.74   <.001   <.001  
     CDR   18.0   4.39   .001   <.001  
2898   DLBCL, CB   4-34   11.8   FR   1.22   2.74   .059   .087  
     CDR   0.40   4.39   .390   .97  
2912   DLBCL, CB   5-51   4.06   FR   3.00   3.35   .155   .211  
     CDR   4.00   3.58   .150   .170  
2914   DLBCL, CB   3-74   8.64   FR   1.50   2.99   .045   .048  
     CDR   8.00   3.69   .023   .022  
3459   DLBCL, CB   1-69   17.6   FR   0.95   2.96   <.001   <.001  
     CDR   1.80   3.55   .145   .502  
3466   DLBCL, CB   1-f   3.73   FR   4.00   3.12   .122   .115  
     CDR   Infinite   3.56   .039   .048  
3518   DLBCL, CB   3-33   4.41   FR   5.00   2.97   .156   .191  
     CDR   2.00   4.28   .151   .176  
3522   DLBCL, CB   4-34   6.87   FR   1.40   2.76   .054   .517  
     CDR   1.00   4.39   .244   .060  
3523   DLBCL, CB   1-46   2.71   FR   Infinite   2.98   .246   .328  
     CDR   3.00   4.40   .125   .104  
3524   DLBCL, CB   3-15   14.9   FR   0.94   2.90   <.001   <.001  
     CDR   1.80   3.44   .143   .393  
3528   DLBCL, CB   1-18   8.11   FR   1.67   2.93   .046   .059  
     CDR   7.00   4.05   .073   .089  
3530   DLBCL, CB   3-07   24.1   FR   2.00   3.07   .077   .216  
     CDR   6.00   4.79   .033   .095  
2616   DLBCL, IB   3-30   9.68   FR   1.20   3.13   .002   .002  
     CDR   6.33   3.87   .013   .013  
2799   DLBCL, IB   4-34   11.6   FR   1.00   2.82   .062   .092  
     CDR   3.00   4.39   .077   .919  
2802   DLBCL, IB   LSG6.1   5.28   FR   1.00   3.23   .223   .208  
     CDR   Infinite   2.95   .293   .307  
2803   DLBCL, IB   3-11   2.80   FR   Infinite   2.95   .118   .095  
     CDR   6.00   4.34   .036   .025  
2911   DLBCL, IB   3-15   2.25   FR   0   3.18   .0549   .027  
     CDR   Infinite   2.95   .421   .421  
3469   DLBCL, IB   3-15   17.2   FR   1.22   3.23   .070   .092  
     CDR   2.00   2.95   .145   .705  
3476   DLBCL, IB   4-04   8.62   FR   1.60   2.70   .032   .0543  
     CDR   3.50   4.09   .103   .119  
3517   DLBCL, IB   3-23   7.80   FR   0.80   2.99   <.001   <.001  
     CDR   6.00   3.55   <.001   <.001  
3525   DLBCL, IB   4-34   2.12   FR   4.00   2.76   .296   .655  
     CDR   0   4.40   .312   .844  
2617   BL/BLL   4-59   5.45   FR   2.00   3.12   .235   .333  
     CDR   2.00   2.98   .305   .504  
2890   BL/BLL   4-61   12.0   FR   2.00   2.75   .053   .066  
 
 
 
 		 CDR
 		 Infinite
 		 4.39
 		 .011
 		 .011
 

FR indicates framework region; CDR, complementarity determining region; R, replacement mutations; S, silent mutations; P-PTLD, polymorphic PTLD; DLBCL, diffuse large B-cell lymphoma; CB, centroblastic; IB, immunoblastic; and BL/BLL, Burkitt lymphoma/Burkitt-like lymphoma.

*

Observed R/S ratio in the FR and CDR.

†

Expected R/S ratio in the FR and CDR.

‡

P is the probability calculated to evaluate whether the excess or the scarcity of R mutations in CDR and FR, respectively, was due to chance alone; PB, P value calculated according to the binomial distribution model; PM, P value calculated according to the multinomial distribution model. Differences were considered statistically significant when P <.05.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal